Sanofi Pasteur and Translate Bio have agreed to expand their existing 2018 collaboration
and licensing agreement to develop mRNA vaccines for infectious diseases. The companies
announced plans to develop an mRNA vaccine for Covid-19 in March..
Sanofi and Translate will build upon their existing collaboration to pursue novel mRNA vaccines aimed
at addressing current and future infectious diseases.
Translate Bio to receive $425 million in upfront payment and common stock equity investment and
overall is eligible to receive up to $1.9 billion of potential milestones/payments as well as tiered royalties
on worldwide sales of developed vaccines
Sanofi to receive exclusive worldwide rights to develop, manufacture and commercialize infectious
disease vaccines using Translate Bio technology
The expanded collaboration brings together Translate Bio’s leading mRNA technology and manufacturing
with Sanofi’s world class vaccine development and distribution
The expansion of this agreement will further unite Translate Bio’s expertise and knowledge from more
than 10 years of mRNA research and development with Sanofi’s leadership in vaccine research and
Under the expansion agreement, Translate Bio will receive a total upfront payment of $425 million,
consisting of a $300 million cash payment and a private placement common stock investment of $125
million at $25.59 per share
Translate Bio will also be eligible for potential future milestones and other payments up to $1.9 billion,
including $450 million of milestones under the 2018 agreement. Of these potential milestones and other
payments, approximately $360 million are anticipated over the next several years, inclusive of COVID-19
vaccine development milestones. In addition, Translate Bio is also eligible to receive tiered royalty
payments based upon worldwide sales of the developed vaccines.
Sanofi Pasteur will pay for all costs during the collaboration term and under this agreement will receive
exclusive worldwide rights for infectious disease vaccines.